Avastin User Fee Date (correction)
This article was originally published in The Pink Sheet Daily
Genentech's Avastin (bevacizumab) has a user fee date in June under a priority review for patients with previously treated metastatic colorectal cancer. "The Pink Sheet" DAILY had reported an incorrect user fee date for the new indication in a May 23 1article
You may also be interested in...
Roche/Genentech's AVANT study of bevacizumab showed no increase in cardiac adverse events, according to an independent data safety monitoring board.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.